Search Results 1161-1170 of 18444 for Immunode

1. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial - Mayo Clinic

   * Known human immunodeficiency virus (HIV) positive. * Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \[HBsAg ...

2. A Study to Assess the Safety, Tolerability, and Effectiveness of KPT-9274 to Treat Patients who have Advanced Solid Malignancies or Non-Hodgkin's Lymphoma - Mayo Clinic

   Known history of Human Immunodeficiency Virus (HIV). HIV testing is not required as part of this study. Known, active hepatitis A, B, or C infection or known ...

3. A Study to Evaluate Nutrition Therapy in Improving Immune System in Bladder Cancer Patients - Mayo Clinic

   ... immunodeficiency and thus alter the biology regarding the study endpoints. ... Patients must not have known active viral infections such as human immunodeficiency ...

4. A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea - Mayo Clinic

   Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal LFTs and undetectable ...

5. Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. - Mayo Clinic

   Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV); Known sensitivity ...

6. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML - Mayo Clinic

   Have current or prior positive test results for human immunodeficiency virus (HIV) or hepatitis B (HBV) or C. Subjects who have positive HBV test results ...

7. A Study Of CSF-1R Inhibitor, AXatilimab For GVHD After HLA-matched Related And Unrelated Donor Allogeneic Stem Cell Transplantation (ABRAXAS) - Mayo Clinic

   Any known infection with human immunodeficiency virus (HIV), HTLV-1. Uncontrolled bacterial, viral, or fungal infections (currently taking medication and ...

8. A Study to Evaluate AVID200 in Myelofibrosis Patients - Mayo Clinic

   Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection. Organ transplant recipients other than bone marrow ...

9. A Study to Evaluate the Effectiveness and Safety of Pembrolizumab Combined with Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days of start ...

10. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

    Known history of human immunodeficiency virus (HIV) infection. Major surgery within 60 days before the first drug administration. Patients must have ...